Metformin

doi:10.1056/NEJM199602293340906

Volume 334:574-579		February 29, 1996		Number 9

Metformin

Clifford J. Bailey, Ph.D., M.R.C.Path., and Robert C. Turner, M.D.

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

Full Text

PDF

Purchase this article

Letters

Add to Personal Archive

Add to Citation Manager

Notify a Friend

E-mail When Cited

PubMed Citation

Metformin (dimethylbiguanide) is an orally administered drugused to lower blood glucose concentrations in patients withnon-insulin-dependent diabetes mellitus (NIDDM).¹ It improvesinsulin sensitivity and thus decreases the insulin resistancethat is prevalent in NIDDM. The efficacy of glycemic controlachieved with metformin is similar to that achieved with sulfonylureas,although their modes of action differ. Metformin can be usedeither as initial therapy or as an additional drug when sulfonylureatherapy alone is inadequate. In this article we shall discussthe pharmacology and clinical use of metformin, which is nowavailable in the United States.

The Burden of Non-Insulin-Dependent Diabetes Mellitus

An estimated 12 million . . . [Full Text of this Article]

The Effects of Improved Glycemic Control

The Pathophysiology of Non-Insulin-Dependent Diabetes Mellitus

Healthful Living and Its Limitations

Sulfonylurea Therapy and Its Limitations

History of Biguanides

Mechanisms of Action of Metformin

Comparison of Sulfonylurea and Metformin Therapy

Initiating and Monitoring Therapy with Metformin

Lactic Acidosis

Use of Metformin Therapy during Intervening Illnesses

Conclusions

Source Information

From the Department of Pharmaceutical and Biological Sciences, Aston University, Birmingham (C.J.B.), and the Diabetes Research Laboratories, Radcliffe Infirmary, Oxford (R.C.T.) — both in the United Kingdom.

Address reprint requests to Dr. Bailey at the Department of Pharmaceutical and Biological Sciences, Aston University, Aston Triangle, Birmingham B4 7ET, United Kingdom.

References

Related Letters:

Metformin-Induced Hemolysis with Jaundice
Lin K.-D., Lin J.-D., Juang J.-H.
Extract | Full Text
N Engl J Med 1998; 339:1860-1861, Dec 17, 1998. Correspondence

This article has been cited by other articles:

Philbrick, A. M., Ernst, M. E., McDanel, D. L., Ross, M. B., Moores, K. G. (2009). Metformin use in renal dysfunction: Is a serum creatinine threshold appropriate?. Am J Health Syst Pharm 66: 2017-2022 [Abstract] [Full Text]
Vianna, R., Brault, A., Martineau, L. C., Couture, R., Arnason, J. T., Haddad, P. S. (2009). In Vivo Anti-Diabetic Activity of the Ethanolic Crude Extract of Sorbus decora C.K.Schneid. (Rosacea): A Medicinal Plant Used by Canadian James Bay Cree Nations to Treat Symptoms Related to Diabetes. Evid Based Complement Alternat Med 0: nep158v1-nep158 [Abstract] [Full Text]
Opie, L. H., Knuuti, J. (2009). The adrenergic-Fatty Acid load in heart failure.. J Am Coll Cardiol 54: 1637-1646 [Abstract] [Full Text]
Fitzgerald, E., Mathieu, S., Ball, A. (2009). Metformin associated lactic acidosis. BMJ 339: b3660-b3660 [Full Text]
Barba, M., Muti, P. (2009). Is it Time to Test Metformin in Breast Cancer Prevention Trials? a Reply to the Authors. Cancer Epidemiol. Biomarkers Prev. 18: 2565-2565 [Full Text]
Biyyani, R. S. R. S., Battula, S., Erhardt, C. A, Korkor, K. (2009). Metformin-induced cholangiohepatitis. BMJ Case Reports 2009: bcr0920080950-bcr0920080950 [Abstract] [Full Text]
Matveyenko, A. V., Dry, S., Cox, H. I., Moshtaghian, A., Gurlo, T., Galasso, R., Butler, A. E., Butler, P. C. (2009). Beneficial Endocrine but Adverse Exocrine Effects of Sitagliptin in the Human Islet Amyloid Polypeptide Transgenic Rat Model of Type 2 Diabetes: Interactions With Metformin. Diabetes 58: 1604-1615 [Abstract] [Full Text]
Nath, N., Khan, M., Paintlia, M. K., Hoda, M. N., Giri, S. (2009). Metformin Attenuated the Autoimmune Disease of the Central Nervous System in Animal Models of Multiple Sclerosis. J. Immunol. 182: 8005-8014 [Abstract] [Full Text]
Shields, W. W., Thompson, K.E., Grice, G.A., Harrison, S.A., Coyle, W.J. (2009). The effect of metformin and standard therapy versus standard therapy alone in nondiabetic patients with insulin resistance and nonalcoholic steatohepatitis (NASH): a pilot trial. Therapeutic Advances in Gastroenterology 2: 157-163 [Abstract]
Cazzaniga, M., Bonanni, B., Guerrieri-Gonzaga, A., Decensi, A. (2009). Is it Time to Test Metformin in Breast Cancer Clinical Trials?. Cancer Epidemiol. Biomarkers Prev. 18: 701-705 [Abstract] [Full Text]
Gundewar, S., Calvert, J. W., Jha, S., Toedt-Pingel, I., Yong Ji, S., Nunez, D., Ramachandran, A., Anaya-Cisneros, M., Tian, R., Lefer, D. J. (2009). Activation of AMP-Activated Protein Kinase by Metformin Improves Left Ventricular Function and Survival in Heart Failure. Circ. Res. 104: 403-411 [Abstract] [Full Text]
Palomba, S., Falbo, A., Zullo, F., Orio, F. Jr. (2009). Evidence-Based and Potential Benefits of Metformin in the Polycystic Ovary Syndrome: A Comprehensive Review. Endocr. Rev. 30: 1-50 [Abstract] [Full Text]
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., Zinman, B. (2009). Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Clin. Diabetes 27: 4-16 [Full Text]
Zhang, T., He, J., Xu, C., Zu, L., Jiang, H., Pu, S., Guo, X., Xu, G. (2009). Mechanisms of metformin inhibiting lipolytic response to isoproterenol in primary rat adipocytes. J Mol Endocrinol 42: 57-66 [Abstract] [Full Text]
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., Zinman, B. (2009). Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Spectr. 22: 6-17 [Full Text]
Swift, T. M. M. (2009). Metformin Use in Patients With Diabetes and Heart Failure: Cause for Concern?. Diabetes Spectr. 22: 18-20 [Full Text]
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., Zinman, B. (2009). Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32: 193-203 [Abstract] [Full Text]
Chitturi, S. (2008). Review: Treatment options for nonalcoholic fatty liver disease. Therapeutic Advances in Gastroenterology 1: 173-189 [Abstract]
Anedda, A., Rial, E., Gonzalez-Barroso, M M. (2008). Metformin induces oxidative stress in white adipocytes and raises uncoupling protein 2 levels. J Endocrinol 199: 33-40 [Abstract] [Full Text]
Forrester, M. (2008). Adult metformin ingestions reported to Texas poison control centers, 2000-2006. Hum Exp Toxicol 27: 575-583 [Abstract]
Bachmakov, I., Glaeser, H., Fromm, M. F., Konig, J. (2008). Interaction of Oral Antidiabetic Drugs With Hepatic Uptake Transporters: Focus on Organic Anion Transporting Polypeptides and Organic Cation Transporter 1. Diabetes 57: 1463-1469 [Abstract] [Full Text]
Hong, Y., Rohatagi, S., Habtemariam, B., Walker, J. R., Schwartz, S. L., Mager, D. E. (2008). Population Exposure-Response Modeling of Metformin in Patients With Type 2 Diabetes Mellitus. J Clin Pharmacol 48: 696-707 [Abstract] [Full Text]
(2008). Metformin: a practical guide to optimising outcomes. British Journal of Diabetes & Vascular Disease 8: 153-156
Cosma, M., Swiglo, B. A., Flynn, D. N., Kurtz, D. M., LaBella, M. L., Mullan, R. J., Elamin, M. B., Erwin, P. J., Montori, V. M. (2008). Insulin Sensitizers for the Treatment of Hirsutism: A Systematic Review and Metaanalyses of Randomized Controlled Trials. J. Clin. Endocrinol. Metab. 93: 1135-1142 [Abstract] [Full Text]
Wu, R.-R., Zhao, J.-P., Guo, X.-F., He, Y.-Q., Fang, M.-S., Guo, W.-B., Chen, J.-D., Li, L.-H. (2008). Metformin Addition Attenuates Olanzapine-Induced Weight Gain in Drug-Naive First-Episode Schizophrenia Patients: A Double-Blind, Placebo-Controlled Study. Am. J. Psychiatry 165: 352-358 [Abstract] [Full Text]
Kim, Y. D., Park, K.-G., Lee, Y.-S., Park, Y.-Y., Kim, D.-K., Nedumaran, B., Jang, W. G., Cho, W.-J., Ha, J., Lee, I.-K., Lee, C.-H., Choi, H.-S. (2008). Metformin Inhibits Hepatic Gluconeogenesis Through AMP-Activated Protein Kinase-Dependent Regulation of the Orphan Nuclear Receptor SHP. Diabetes 57: 306-314 [Abstract] [Full Text]
Nestler, J. E. (2008). Metformin for the Treatment of the Polycystic Ovary Syndrome. NEJM 358: 47-54 [Full Text]
Fowler, M. J. (2007). Diabetes Treatment, Part 2: Oral Agents for Glycemic Management. Clin. Diabetes 25: 131-134 [Full Text]
Palomba, S., Falbo, A., Russo, T., Manguso, F., Tolino, A., Zullo, F., De Feo, P., Orio, F. Jr. (2007). Insulin Sensitivity after Metformin Suspension in Normal-Weight Women with Polycystic Ovary Syndrome. J. Clin. Endocrinol. Metab. 92: 3128-3135 [Abstract] [Full Text]
Zhang, L., He, H., Balschi, J. A. (2007). Metformin and phenformin activate AMP-activated protein kinase in the heart by increasing cytosolic AMP concentration. Am. J. Physiol. Heart Circ. Physiol. 293: H457-H466 [Abstract] [Full Text]
Kaminski, M., Kiessling, M., Suss, D., Krammer, P. H., Gulow, K. (2007). Novel Role for Mitochondria: Protein Kinase C{theta}-Dependent Oxidative Signaling Organelles in Activation-Induced T-Cell Death. Mol. Cell. Biol. 27: 3625-3639 [Abstract] [Full Text]
Tolman, K. G., Fonseca, V., Dalpiaz, A., Tan, M. H. (2007). Spectrum of Liver Disease in Type 2 Diabetes and Management of Patients With Diabetes and Liver Disease. Diabetes Care 30: 734-743 [Full Text]
Karim, A., Slater, M., Bradford, D., Schwartz, L., Zhao, Z., Cao, C., Laurent, A. (2007). Oral Antidiabetic Drugs: Bioavailability Assessment of Fixed-Dose Combination Tablets of Pioglitazone and Metformin. Effect of Body Weight, Gender, and Race on Systemic Exposures of Each Drug. J Clin Pharmacol 47: 37-47 [Abstract] [Full Text]
Duncan, A. I., Koch, C. G., Xu, M., Manlapaz, M., Batdorf, B., Pitas, G., Starr, N. (2007). Recent Metformin Ingestion Does Not Increase In-Hospital Morbidity or Mortality After Cardiac Surgery. Anesth. Analg. 104: 42-50 [Abstract] [Full Text]
Skaer, T. L., Sclar, D. A., Robison, L. M. (2006). Trends in the Prescribing of Oral Agents for the Management of Type 2 Diabetes Mellitus in the United States, 1990-2001: Does Type of Insurance Influence Access to Innovation?. The Diabetes Educator 32: 940-953 [Abstract] [Full Text]
Ting, R. Z.-W., Szeto, C. C., Chan, M. H.-M., Ma, K. K., Chow, K. M. (2006). Risk factors of vitamin B12 deficiency in patients receiving metformin.. Arch Intern Med 166: 1975-1979 [Abstract] [Full Text]
Nathan, D. M., Buse, J. B., Davidson, M. B., Heine, R. J., Holman, R. R., Sherwin, R., Zinman, B. (2006). Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 29: 1963-1972 [Full Text]
Bertrand, L., Ginion, A., Beauloye, C., Hebert, A. D., Guigas, B., Hue, L., Vanoverschelde, J.-L. (2006). AMPK activation restores the stimulation of glucose uptake in an in vitro model of insulin-resistant cardiomyocytes via the activation of protein kinase B. Am. J. Physiol. Heart Circ. Physiol. 291: H239-H250 [Abstract] [Full Text]
Luchsinger, J. A. (2006). A Work in Progress: The Metabolic Syndrome. Sci Aging Knowl Environ 2006: pe19-pe19 [Abstract] [Full Text]
Srinivasan, S., Ambler, G. R., Baur, L. A., Garnett, S. P., Tepsa, M., Yap, F., Ward, G. M., Cowell, C. T. (2006). Randomized, Controlled Trial of Metformin for Obesity and Insulin Resistance in Children and Adolescents: Improvement in Body Composition and Fasting Insulin. J. Clin. Endocrinol. Metab. 91: 2074-2080 [Abstract] [Full Text]
Gross, J. L., Friedman, R., Silveiro, S. P., Hellman, R. N., Tepel, M., Barrett, B. J., Parfrey, P. S. (2006). Preventing nephropathy induced by contrast medium.. NEJM 354: 1853-1855 [Full Text]
Macklon, N. S., Stouffer, R. L., Giudice, L. C., Fauser, B. C. J. M. (2006). The Science behind 25 Years of Ovarian Stimulation for in Vitro Fertilization. Endocr. Rev. 27: 170-207 [Abstract] [Full Text]
Drucker, D. J. (2006). The evidence for achieving glycemic control with incretin mimetics.. The Diabetes Educator 32: 72S-81S [Full Text]
Bowker, S. L., Majumdar, S. R., Veugelers, P., Johnson, J. A. (2006). Increased Cancer-Related Mortality for Patients With Type 2 Diabetes Who Use Sulfonylureas or Insulin. Diabetes Care 29: 254-258 [Abstract] [Full Text]
Brown, F. M., Wyckoff, J., Rowan, J. A., Jovanovic, L., Sacks, D. A., Briggs, G. G. (2006). Metformin in Pregnancy: Its time has not yet come. Diabetes Care 29: 485-486 [Full Text]
(2006). Changes in Weight and Glucose Tolerance During Treatment With Mirtazapine. Diabetes Care 29: 170-171
Sharabash, H. M., Remington, T. L., Mar, P., Winston, R., Walker, P. C., Pollmacher, T. (2006). Changes in weight and glucose tolerance during treatment with mirtazapine.. Diabetes Care 29: 170-170 [Full Text]
Yilmaz, M., Bukan, N., Ayvaz, G., Karakoc, A., Toruner, F., Cakir, N., Arslan, M. (2005). The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome. Hum Reprod 20: 3333-3340 [Abstract] [Full Text]
Mallare, J. T., Karabell, A. H., Velasquez-Mieyer, P., Stender, S. R.S., Christensen, M. L. (2005). Current and Future Treatment of Metabolic Syndrome and Type 2 Diabetes in Children and Adolescents. Diabetes Spectr. 18: 220-228 [Abstract] [Full Text]
Fantus, I. G. (2005). Metformin's contraindications: needed for now. CMAJ 173: 505-507 [Full Text]
Detaille, D., Guigas, B., Chauvin, C., Batandier, C., Fontaine, E., Wiernsperger, N., Leverve, X. (2005). Metformin Prevents High-Glucose-Induced Endothelial Cell Death Through a Mitochondrial Permeability Transition-Dependent Process. Diabetes 54: 2179-2187 [Abstract] [Full Text]
Lada, P., Idrees, U. (2005). Toxicity of Oral Agents Used to Treat Diabetes. Journal of Pharmacy Practice 18: 145-156 [Abstract]
Bailey, C. J. (2005). Overview of new and developing pharmacological treatments. Eur Heart J Suppl 7: D23-D26 [Full Text]
Karlsson, H. K.R., Hallsten, K., Bjornholm, M., Tsuchida, H., Chibalin, A. V., Virtanen, K. A., Heinonen, O. J., Lonnqvist, F., Nuutila, P., Zierath, J. R. (2005). Effects of Metformin and Rosiglitazone Treatment on Insulin Signaling and Glucose Uptake in Patients With Newly Diagnosed Type 2 Diabetes: A Randomized Controlled Study. Diabetes 54: 1459-1467 [Abstract] [Full Text]
Kimmel, B., Inzucchi, S. E. (2005). Oral Agents for Type 2 Diabetes: An Update. Clin. Diabetes 23: 64-76 [Abstract] [Full Text]
Omari, A., Yue, D. K, Twigg, S. M (2005). Exercise, metformin and hypoglycaemia: a neglected entity. British Journal of Diabetes & Vascular Disease 5: 106-108 [Abstract]
Cheng, A. Y.Y., Fantus, I. G. (2005). Oral antihyperglycemic therapy for type 2 diabetes mellitus. CMAJ 172: 213-226 [Abstract] [Full Text]
Lindenfeld, J., Page, R. L. II, Zolty, R., Shakar, S. F., Levi, M., Lowes, B., Wolfel, E. E., Miller, G. G. (2005). Drug Therapy in the Heart Transplant Recipient: Part III: Common Medical Problems. Circulation 111: 113-117 [Full Text]
Gross, J. L., de Azevedo, M. J., Silveiro, S. P., Canani, L. H., Caramori, M. L., Zelmanovitz, T. (2005). Diabetic Nephropathy: Diagnosis, Prevention, and Treatment. Diabetes Care 28: 164-176 [Abstract] [Full Text]
Tolman, K. G., Fonseca, V., Tan, M. H., Dalpiaz, A. (2004). Narrative Review: Hepatobiliary Disease in Type 2 Diabetes Mellitus. ANN INTERN MED 141: 946-956 [Abstract] [Full Text]
Schernthaner, G., Matthews, D. R., Charbonnel, B., Hanefeld, M., Brunetti, P., on Behalf of the Quarter Study Group, (2004). Efficacy and Safety of Pioglitazone Versus Metformin in Patients with Type 2 Diabetes Mellitus: A Double-Blind, Randomized Trial. J. Clin. Endocrinol. Metab. 89: 6068-6076 [Abstract] [Full Text]
Henquin, J.-C. (2004). Pathways in Beta-Cell Stimulus-Secretion Coupling as Targets for Therapeutic Insulin Secretagogues. Diabetes 53: S48-S58 [Abstract] [Full Text]
Leclerc, I., Rutter, G. A. (2004). AMP-Activated Protein Kinase: A New Beta-Cell Glucose Sensor?: Regulation by Amino Acids and Calcium Ions. Diabetes 53: S67-S74 [Abstract] [Full Text]
Klein, J., Westphal, S., Kraus, D., Meier, B., Perwitz, N., Ott, V., Fasshauer, M., Klein, H H. (2004). Metformin inhibits leptin secretion via a mitogen-activated protein kinase signalling pathway in brown adipocytes. J Endocrinol 183: 299-307 [Abstract] [Full Text]
Bettmann, M. A. (2004). Frequently Asked Questions: Iodinated Contrast Agents. RadioGraphics 24: S3-S10 [Abstract] [Full Text]
Yasuda, N., Inoue, T., Nagakura, T., Yamazaki, K., Kira, K., Saeki, T., Tanaka, I. (2004). Metformin Causes Reduction of Food Intake and Body Weight Gain and Improvement of Glucose Intolerance in Combination with Dipeptidyl Peptidase IV Inhibitor in Zucker fa/fa Rats. J. Pharmacol. Exp. Ther. 310: 614-619 [Abstract] [Full Text]
Chan, A. Y. M., Soltys, C.-L. M., Young, M. E., Proud, C. G., Dyck, J. R. B. (2004). Activation of AMP-activated Protein Kinase Inhibits Protein Synthesis Associated with Hypertrophy in the Cardiac Myocyte. J. Biol. Chem. 279: 32771-32779 [Abstract] [Full Text]
Edwards, C M. B (2004). GLP-1: target for a new class of antidiabetic agents?. JRSM 97: 270-274 [Full Text]
Leclerc, I., Woltersdorf, W. W., da Silva Xavier, G., Rowe, R. L., Cross, S. E., Korbutt, G. S., Rajotte, R. V., Smith, R., Rutter, G. A. (2004). Metformin, but not leptin, regulates AMP-activated protein kinase in pancreatic islets: impact on glucose-stimulated insulin secretion. Am. J. Physiol. Endocrinol. Metab. 286: E1023-E1031 [Abstract] [Full Text]
Grant, R. W., Pirraglia, P. A., Meigs, J. B., Singer, D. E. (2004). Trends in Complexity of Diabetes Care in the United States From 1991 to 2000. Arch Intern Med 164: 1134-1139 [Abstract] [Full Text]
Kirby, M. (2004). Initiating insulin in patients with type 2 diabetes within primary care. British Journal of Diabetes & Vascular Disease 4: 122-125 [Abstract]
Koski, R. R. (2004). Oral Antidiabetic Agents: A Comparative Review. Journal of Pharmacy Practice 17: 39-48 [Abstract]
Price, G. (2003). Metformin lactic acidosis, acute renal failure and rofecoxib. Br J Anaesth 91: 909-910 [Abstract] [Full Text]
Rose, S. R. (2003). Drug Therapy in Polycystic Ovarian Syndrome. AAP Grand Rounds 10: 65-66 [Full Text]
Ibanez, L., de Zegher, F. (2003). Flutamide-Metformin Therapy to Reduce Fat Mass in Hyperinsulinemic Ovarian Hyperandrogenism: Effects in Adolescents and in Women on Third-Generation Oral Contraception. J. Clin. Endocrinol. Metab. 88: 4720-4724 [Abstract] [Full Text]
Schier, J. G, Hoffman, R. S, Nelson, L. S (2003). Metformin-induced acidosis due to a warfarin adverse drug event. The Annals of Pharmacotherapy 37: 1145-1145 [Full Text]
Dandona, P., Aljada, A., Chaudhuri, A., Bandyopadhyay, A. (2003). The Potential Influence of Inflammation and Insulin Resistance on the Pathogenesis and Treatment of Atherosclerosis-Related Complications in Type 2 Diabetes. J. Clin. Endocrinol. Metab. 88: 2422-2429 [Full Text]
Ibanez, L., Ong, K., Ferrer, A., Amin, R., Dunger, D., de Zegher, F. (2003). Low-Dose Flutamide-Metformin Therapy Reverses Insulin Resistance and Reduces Fat Mass in Nonobese Adolescents with Ovarian Hyperandrogenism. J. Clin. Endocrinol. Metab. 88: 2600-2606 [Abstract] [Full Text]
Iida, K. T., Kawakami, Y., Suzuki, M., Shimano, H., Toyoshima, H., Sone, H., Shimada, K., Iwama, Y., Watanabe, Y., Mokuno, H., Kamata, K., Yamada, N. (2003). Effect of thiazolidinediones and metformin on LDL oxidation and aortic endothelium relaxation in diabetic GK rats. Am. J. Physiol. Endocrinol. Metab. 284: E1125-E1130 [Abstract] [Full Text]
Edwards, C.M.B., Barton, M.A., Snook, J., David, M., Mak, V.H.F., Chowdhury, T.A. (2003). Metformin-associated lactic acidosis in a patient with liver disease. QJM 96: 315-316 [Full Text]
Zangeneh, F., Kudva, Y. C., Basu, A. (2003). Insulin Sensitizers. Mayo Clin Proc. 78: 471-479 [Abstract]
Schultes, B., Oltmanns, K. M., Kern, W., Fehm, H. L., Born, J., Peters, A. (2003). Modulation of Hunger by Plasma Glucose and Metformin. J. Clin. Endocrinol. Metab. 88: 1133-1141 [Abstract] [Full Text]
Gunton, J. E., Delhanty, P. J. D., Takahashi, S.-I., Baxter, R. C. (2003). Metformin Rapidly Increases Insulin Receptor Activation in Human Liver and Signals Preferentially through Insulin-Receptor Substrate-2. J. Clin. Endocrinol. Metab. 88: 1323-1332 [Abstract] [Full Text]
Phillips, S. A., Ciaraldi, T. P., Kong, A. P.S., Bandukwala, R., Aroda, V., Carter, L., Baxi, S., Mudaliar, S. R., Henry, R. R. (2003). Modulation of Circulating and Adipose Tissue Adiponectin Levels by Antidiabetic Therapy. Diabetes 52: 667-674 [Abstract] [Full Text]
Phillips, P., Karrasch, J., Scott, R., Wilson, D., Moses, R. (2003). Acarbose Improves Glycemic Control in Overweight Type 2 Diabetic Patients Insufficiently Treated With Metformin. Diabetes Care 26: 269-273 [Abstract] [Full Text]
Virtanen, K. A., Hallsten, K., Parkkola, R., Janatuinen, T., Lonnqvist, F., Viljanen, T., Ronnemaa, T., Knuuti, J., Huupponen, R., Lonnroth, P., Nuutila, P. (2003). Differential Effects of Rosiglitazone and Metformin on Adipose Tissue Distribution and Glucose Uptake in Type 2 Diabetic Subjects. Diabetes 52: 283-290 [Abstract] [Full Text]
Freemark, M. (2003). Pharmacologic Approaches to the Prevention of Type 2 Diabetes in High Risk Pediatric Patients. J. Clin. Endocrinol. Metab. 88: 3-13 [Full Text]
Khan, J. K, Pallaki, M., Tolbert, S. R, Hornick, T. R (2003). Lactic Acidemia Associated with Metformin. The Annals of Pharmacotherapy 37: 66-69 [Abstract] [Full Text]
Seli, E., Duleba, A. J. (2002). Should patients with polycystic ovarian syndrome be treated with metformin?. Hum Reprod 17: 2230-2236 [Abstract] [Full Text]
Stepensky, D., Friedman, M., Raz, I., Hoffman, A. (2002). Pharmacokinetic-Pharmacodynamic Analysis of the Glucose-Lowering Effect of Metformin in Diabetic Rats Reveals First-Pass Pharmacodynamic Effect. Drug Metab. Dispos. 30: 861-868 [Abstract] [Full Text]
Hinke, S. A., McIntosh, C. H. S., Hoffmann, T., Kuhn-Wache, K., Wagner, L., Bar, J., Manhart, S., Wermann, M., Pederson, R. A., Demuth, H.-U. (2002). On Combination Therapy of Diabetes With Metformin and Dipeptidyl Peptidase IV Inhibitors. Diabetes Care 25: 1490-1491 [Full Text]
Kirpichnikov, D., McFarlane, S. I., Sowers, J. R. (2002). Metformin: An Update. ANN INTERN MED 137: 25-33 [Abstract] [Full Text]
Ibanez, L., Valls, C., Ferrer, A., Ong, K., Dunger, D. B., de Zegher, F. (2002). Additive Effects of Insulin-Sensitizing and Anti-Androgen Treatment in Young, Nonobese Women with Hyperinsulinism, Hyperandrogenism, Dyslipidemia, and Anovulation. J. Clin. Endocrinol. Metab. 87: 2870-2874 [Abstract] [Full Text]
Calabrese, A. T., Coley, K. C., DaPos, S. V., Swanson, D., Rao, R. H. (2002). Evaluation of Prescribing Practices: Risk of Lactic Acidosis With Metformin Therapy. Arch Intern Med 162: 434-437 [Abstract] [Full Text]
Yanovski, S. Z., Yanovski, J. A. (2002). Obesity. NEJM 346: 591-602 [Full Text]
Kim, Y.-B., Ciaraldi, T. P., Kong, A., Kim, D., Chu, N., Mohideen, P., Mudaliar, S., Henry, R. R., Kahn, B. B. (2002). Troglitazone but not Metformin Restores Insulin-Stimulated Phosphoinositide 3-Kinase Activity and Increases p110{beta} Protein Levels in Skeletal Muscle of Type 2 Diabetic Subjects. Diabetes 51: 443-448 [Abstract] [Full Text]
Inzucchi, S. E. (2002). Oral Antihyperglycemic Therapy for Type 2 Diabetes: Scientific Review. JAMA 287: 360-372 [Abstract] [Full Text]
Standeven, K. F., Ariens, R. A.S., Whitaker, P., Ashcroft, A. E., Weisel, J. W., Grant, P. J. (2002). The Effect of Dimethylbiguanide on Thrombin Activity, FXIII Activation, Fibrin Polymerization, and Fibrin Clot Formation. Diabetes 51: 189-197 [Abstract] [Full Text]
Fruehwald-Schultes, B., Kern, W., Oltmanns, K. M., Sopke, S., Toschek, B., Born, J., Fehm, H. L., Peters, A. (2001). Metformin Does Not Adversely Affect Hormonal and Symptomatic Responses to Recurrent Hypoglycemia. J. Clin. Endocrinol. Metab. 86: 4187-4192 [Abstract] [Full Text]
Scarpello, J. H. (2001). Review: Optimal dosing strategies for maximising the clinical response to metformin in type 2 diabetes. British Journal of Diabetes & Vascular Disease 1: 28-36 [Abstract]

Comments and questions? Please contact us.